Resumo
Definição
História e exame físico
Principais fatores diagnósticos
- vírus da imunodeficiência humana (HIV)-positivo
Outros fatores diagnósticos
- candidíase orofaríngea
- pneumonia bacteriana recorrente
- perda de peso
- duração prolongada dos sintomas (pacientes HIV-positivos)
- início rápido dos sintomas (pacientes HIV-negativos)
- febre
- tosse seca
- dispneia
- fadiga
- exame normal do tórax
- taquicardia
- taquipneia ou dificuldade respiratória
- cianose
- manifestações extrapulmonares
- dor torácica pleurítica
- murmúrio vesicular unilateral diminuído
Fatores de risco
- contagem de células CD4 abaixo de 200 células/microlitro
- pacientes imunocomprometidos
- corticoterapia crônica
- pneumonia por Pneumocystis anterior
Investigações diagnósticas
Primeiras investigações a serem solicitadas
- radiografia torácica
- gasometria arterial
- nível de lactato desidrogenase (LDH) sérica
- escarro induzido
Investigações a serem consideradas
- tomografia computadorizada de alta resolução (TCAR) do tórax
- teste de função pulmonar
- broncoscopia e lavagem broncoalveolar (LBA)
- biópsia
Novos exames
- reação em cadeia da polimerase
- nível de S-adenosilmetionina no plasma
- nível de (1,3)-beta-D-glicano sérico
Algoritmo de tratamento
risco elevado de infecção por pneumonia por Pneumocystis (PPC)
adultos ou adolescentes: HIV-positivo
crianças: HIV-positivas ou sob risco de HIV
adultos ou adolescentes imunocomprometidos: HIV-negativos e não receptores de transplante de órgão sólido
adultos, adolescentes ou crianças imunocomprometidos: HIV-negativos e receptores de transplante de órgão sólido
tratamento da infecção por pneumonia por Pneumocystis (PPC) concluído com sucesso
Colaboradores
Autores
Alison Morris, MD, MS
Professor of Medicine
Pulmonary, Allergy, Critical Care, and Sleep Medicine
University of Pittsburgh
Pittsburgh
PA
Declarações
AM is an author of a number of references cited in this topic.
Ioannis Konstantinidis, MD, MS
Assistant Professor of Medicine
Pulmonary, Allergy, Critical Care, and Sleep Medicine
University of Pittsburgh
Pittsburgh
PA
Declarações
IK declares that he has no competing interests.
Agradecimentos
Dr Alison Morris and Dr Ioannis Konstantinidis would like to gratefully acknowledge Dr Eric Nolley and Dr Matthew Gingo, previous contributors to this topic.
Declarações
EN and MG declare that they have no competing interests.
Revisores
Peter D. Walzer, MD, MSc
Associate Chief of Staff for Research
Cincinnati VA Medical Center
Professor of Medicine
University of Cincinnati
Cincinnati
OH
Declarações
PDW declares that he has no competing interests.
David Spencer, MBChB(UCT), MMed (Wits)
Specialist Physician and Consultant
Toga Laboratory and Kimera Consultants
Edenvale
Johannesburg
South Africa
Declarações
DS declares that he has no competing interests.
Graeme Meintjes, MBChB, MRCP, FCP, DipHIVMan
Infectious Diseases Physician
Institute of Infectious Diseases and Molecular Medicine
Faculty of Health Sciences
University of Cape Town
Observatory
South Africa
Declarações
GM declares that he has no competing interests.
Referências
Principais artigos
Palella FJ, Delaney KM, Moorman FC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998 Mar 26;338(13):853-60.Texto completo Resumo
National Institutes of Health, Centers for Disease Control and Prevention, HIV Medicine Association of the Infectious Diseases Society of America, Pediatric Infectious Diseases Society, and American Academy of Pediatrics. Panel on Opportunistic Infections in Children with and Exposed to HIV. Guidelines for the prevention and treatment of opportunistic infections in children with and exposed to HIV: Pneumocystis jirovecii pneumonia. Nov 2013 [internet publication].Texto completo
National Institutes of Health, Centers for Disease Control and Prevention, HIV Medicine Association, and Infectious Diseases Society of America. Panel on Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV. Pneumocystis pneumonia. Sep 2024 [internet publication].Texto completo
Taplitz RA, Kennedy EB, Bow EJ, et al. Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA clinical practice guideline update. J Clin Oncol. 2018 Oct 20;36(30):3043-54.Texto completo Resumo
Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant. 2009 Oct;15(10):1143-238.Texto completo Resumo
Fishman JA, Gans H, AST Infectious Diseases Community of Practice. Pneumocystis jiroveci in solid organ transplantation: guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019 Sep;33(9):e13587. Resumo
Limper AH, Knox KS, Sarosi GA, et al. An official American Thoracic Society statement: treatment of fungal infections in adult pulmonary and critical care patients. Am J Respir Crit Care Med. 2011 Jan 1;183(1):96-128.Texto completo Resumo
Ewald H, Raatz H, Boscacci R, et al. Adjunctive corticosteroids for Pneumocystis jiroveci pneumonia in patients with HIV infection. Cochrane Database Syst Rev. 2015 Apr 2;(4):CD006150.Texto completo Resumo
Cooley L, Dendle C, Wolf J, et al. Consensus guidelines for diagnosis, prophylaxis and management of Pneumocystis jirovecii pneumonia in patients with haematological and solid malignancies, 2014. Intern Med J. 2014 Dec;44(12b):1350-63.Texto completo Resumo
Maertens J, Cesaro S, Maschmeyer G, et al. ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients. J Antimicrob Chemother. 2016 Sep;71(9):2397-404.Texto completo Resumo
Classen AY, Henze L, von Lilienfeld-Toal M, et al. Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in patients with hematologic malignancies and solid tumors: 2020 updated guidelines of the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology (AGIHO/DGHO). Ann Hematol. 2021 Jun;100(6):1603-20.Texto completo Resumo
Artigos de referência
Uma lista completa das fontes referenciadas neste tópico está disponível para os usuários com acesso total ao BMJ Best Practice.
Diagnósticos diferenciais
- Doença do coronavírus 2019 (COVID-19)
- Pneumonia bacteriana
- Coccidioidomicose
Mais Diagnósticos diferenciaisDiretrizes
- Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: pneumocystis pneumonia
- Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in patients with hematologic malignancies and solid tumors
Mais Diretrizes
Conectar-se ou assinar para acessar todo o BMJ Best Practice
O uso deste conteúdo está sujeito ao nosso aviso legal